Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Pogled internista onkologa na sistemsko zdravljenje raka požiralnika
Authors:ID Reberšek, Martina (Author)
ID Mesti, Tanja (Author)
ID Boc, Marko (Author)
Files:.pdf PDF - Presentation file, download (377,91 KB)
MD5: D26475C23486C6121931D1D64470AC28
PID: 20.500.12556/dirros/541c461b-f955-47b6-b7ae-804060bc7e04
 
Language:Slovenian
Typology:1.08 - Published Scientific Conference Contribution
Organization:Logo OI - Institute of Oncology
Keywords:onkologija, rak požiralnika, sistemsko zdravljenje, rak prebavil
Publication status:Published
Publication version:Version of Record
Year of publishing:2014
Number of pages:str. 34-38, 74
Numbering:Letn. 18, št. 1
PID:20.500.12556/DiRROS-9019 New window
UDC:616.3-006
ISSN on article:1408-1741
URN:URN:NBN:SI:doc-H68I2RZN
COBISS.SI-ID:1808507 New window
Copyright:by Authors
Publication date in DiRROS:31.08.2018
Views:3461
Downloads:913
Metadata:XML DC-XML DC-RDF
:
REBERŠEK, Martina, MESTI, Tanja and BOC, Marko, 2014, Pogled internista onkologa na sistemsko zdravljenje raka požiralnika. In : Šola: tumorji prebavil II, Ljubljana, 15. 11. 2013 [online]. Published Scientific Conference Contribution. 2014. p. 34–38, 74. [Accessed 31 March 2025]. Retrieved from: https://dirros.openscience.si/IzpisGradiva.php?lang=eng&id=9019
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Šola: tumorji prebavil II, Ljubljana, 15. 11. 2013
Publisher:Onkološki inštitut
COBISS.SI-ID:1807227 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Language:English
Title:[Treatment of oesophageal cancer from the medical oncologists' point of view]
Abstract:The incidence of carcinoma of the oesophagus in Slovenia is small and has not changed in years. The prognosis of patients with metastatic carcinoma of the oesophagus is poor, with less than 10% 5-year survival. In the early stages of the disease, we recommend surgical treatment in combination with neoadjuvant chemoradiation for squamous cell carcinoma or perioperative systemic chemotherapy for adenocarcinoma of the gastroesophageal junction. In locoregionally advanced carcinoma, we recommend neoadjuvant chemoradiation. In the case of cervical carcinoma of the oesophagus or in high-risk patients not fit for surgery, we recommend definitive chemoradiation. The most optimal systemic therapy for metastatic disease is selected based on the general state of the patient, his concurrent diseases, the expected toxicity of systemic therapy, and HER2 status in patients with adenocarcinoma. For first-line treatment, we recommend doublet chemotherapy, mainly due to a better toxicity profile. In the case of HER2-positive adenocarcinoma, doublet may be combined with trastuzumab. In patients who are in good general condition, we can try with a combination of three cytostatics. For patients in poor general condition, only palliative supportive care is recommended, since the benefit of such treatment outweighs the potential treatment complications. We are eagerly awaiting the results of the ongoing clinical trials of new combinations of cytostatics and targeted drugs, hoping for more effective combinations of drugs that would enable us to treat patients with metastatic carcinoma of the oesophagus and gastroesophageal junction more effectively


Archive

niGradiv

Back